Rexulti denied by insurance? Appeal and win.
A Rexulti denial is rarely the final word. It is usually a starting point in a process, and most denials come down to one fact: Rexulti is a brand-only drug with no generic, so plans want to see that cheaper generic antipsychotics were tried first. The appeals that flip these denials document the specific generics already tried and why they failed, then map that history directly to the plan's own step-therapy or prior-authorization rules.
Reviewed by the Apellica Appeals Team · Updated June 2026
Carrier names and logos are trademarks of their respective owners. Apellica is independent and not affiliated with any insurance carrier or carrier's appeal program.
Rexulti (brexpiprazole) is FDA-approved for the treatment of schizophrenia in adults and in adolescents aged 13 and older. It is also approved as an add-on (adjunctive) therapy alongside an antidepressant for adults with major depressive disorder who have not responded adequately to the antidepressant alone. In 2023 it became the first FDA-approved treatment for agitation associated with dementia due to Alzheimer disease in adults. It is not approved for as-needed use, and it is not approved for dementia-related psychosis without agitation.
Why Rexulti gets denied
- Step therapy not met: because Rexulti is brand-only with no generic, most plans first require a documented trial and failure of one or more generic atypical antipsychotics (often aripiprazole, plus risperidone, olanzapine, quetiapine, ziprasidone, or paliperidone).
- Prior-authorization criteria not documented: the plan may require proof of the specific diagnosis, age criteria, and inadequate response or intolerance to the required number of prior agents, and the request was submitted without that detail.
- Non-formulary or high-tier placement: many plans place Rexulti on a non-preferred or specialty tier, triggering a formulary or tier-exception requirement before coverage.
- Indication or label-limit concerns: for the Alzheimer agitation use, plans may flag the boxed warning on increased mortality in elderly dementia patients, or deny prescribing that falls outside the approved indications (for example as-needed use or dementia psychosis without agitation).
What a winning appeal includes
- A clear diagnosis with the correct ICD-10 code (for example F20.9 schizophrenia, F32/F33 major depressive disorder for the adjunctive use, or F03 dementia with the documented agitation behaviors for the Alzheimer indication) and confirmation the patient meets the age criteria.
- A documented history of the generic antipsychotics already tried, with dates, doses, duration, and the specific reason each failed or could not be tolerated, matched to the number the plan requires.
- A letter of medical necessity that maps the patient's history point by point to the plan's published step-therapy or PA criteria and explains why Rexulti is the appropriate next agent.
- Supporting clinical detail such as PHQ-9 or symptom-rating scores for depression, prior hospitalization or relapse records for schizophrenia, or documented agitation episodes and a non-as-needed dosing plan for the Alzheimer indication.
How we approach the appeal
Identify which denial you have, because the path differs. If the drug is simply non-formulary or on a high tier, file a formulary or tier exception. If it is a step-therapy or prior-authorization denial, appeal with documentation that satisfies the plan's stated rules, quoting the plan's own criteria back to it (for example, language requiring "an inadequate response to or intolerance of" a set number of generic atypical antipsychotics, "one of which must be aripiprazole"). When generics genuinely failed or are contraindicated, request a step-therapy override or medical-necessity exception and attach the trial-and-failure history that proves the criterion is met.
Rexulti appeal letter template
Copy this Rexulti appeal letter, fill in the brackets, and send it within your deadline. It is built on what overturns Atypical (second-generation) antipsychotic, serotonin-dopamine activity modulator denials.
[Date] [Your name] · Member ID [ID] · Rx claim # [#] [Insurer or PBM] - Appeals Department Re: Appeal of Rexulti denial I am appealing the denial of Rexulti (brexpiprazole). I request that the denial be overturned and Rexulti approved. 1. The denial. [Insurer] denied Rexulti stating, verbatim: "[paste the exact denial reason from your letter]." 2. Medical necessity. Rexulti is medically necessary for my condition. Identify which denial you have, because the path differs. If the drug is simply non-formulary or on a high tier, file a formulary or tier exception. If it is a step-therapy or prior-authorization denial, appeal with documentation that satisfies the plan's stated rules, quoting the plan's own criteria back to it (for example, language requiring "an inadequate response to or intolerance of" a set number of generic atypical antipsychotics, "one of which must be aripiprazole"). When generics genuinely failed or are contraindicated, request a step-therapy override or medical-necessity exception and attach the trial-and-failure history that proves the criterion is met. 3. Step-therapy or formulary exception (if that was the reason): I have tried and failed [preferred drug(s)], with pharmacy records attached, or the preferred alternative is contraindicated because [reason]. I request a formulary or step-therapy exception. 4. My request. Approve Rexulti within the timeframe required by law. If the denial is upheld, please provide the specific criteria used, the reviewing clinician's credentials, and external-review instructions. Attached: prescriber letter of medical necessity, pharmacy and prior-trial records, and supporting clinical notes. Sincerely, [Your name]
Want it built and filed for you? Use the free generator, or have Apellica do it.
Internal appeals: 30 days pre-service, 60 days post-service, 72 hours urgent. File within 180 days of the denial.
$0 upfront. We assess fit first, then build and file the appeal for you.
- · The denial letter and your Explanation of Benefits (EOB)
- · Insurance ID, plan name, and the claim or prior-authorization number
- · Diagnosis with ICD-10 code and the prescriber's clinical notes
- · A record of treatments already tried and how they worked
Appealing a Rexulti denial by insurer
The path depends on who manages your benefit. The most common:
Coverage runs through the pharmacy benefit. Appeal the coverage determination and, when the drug is non-formulary, file a formulary or tier exception with a provider attestation that covered alternatives are unsuitable.
Publishes detailed prior-authorization criteria. A denial usually means a criterion was not documented. Appeal through a coverage review, with a formulary exception for excluded drugs.
Administers many UnitedHealthcare and employer plans. Appeals and exceptions follow the plan's published PA criteria; expedited review exists for urgent cases.
Internal appeal first, then independent external review. Pre-service decisions are generally made within 30 days, urgent within 72 hours.
Internal appeals and external review; pharmacy denials often route through OptumRx criteria.
Independent state plans, so criteria vary. Match the appeal to your specific BCBS plan, internal appeal first, then external review.
Frequently asked questions
Why does my plan want me to try other antipsychotics before Rexulti?
Rexulti is a brand-name drug with no generic version, so it is more expensive than generic options. Most plans use step therapy that requires a documented trial of one or more generic atypical antipsychotics first, frequently including aripiprazole, which is closely related to brexpiprazole. If you have already tried and failed those drugs, or cannot take them, that history is exactly what your appeal needs to document.
Is there a generic for Rexulti I can use instead?
As of now there is no FDA-approved generic for brexpiprazole, so Rexulti is brand-only. That is part of why it gets denied. If your prescriber specifically needs Rexulti rather than a generic alternative, the appeal should explain why the available generic antipsychotics are not appropriate for you, supported by your treatment history.
Can Rexulti be covered for agitation in Alzheimer dementia?
Yes. Rexulti is FDA-approved for agitation associated with dementia due to Alzheimer disease, so coverage is possible. Plans may scrutinize these requests because the label carries a boxed warning about increased risk of death in elderly patients with dementia. A strong appeal documents the specific agitation behaviors, confirms the diagnosis, and shows the prescriber is using scheduled (not as-needed) dosing consistent with the approved use.
Rexulti denied? We fight it for you.
$0 upfront. Two-minute intake. We confirm fit and reply within one business day with the right path for your situation.
Start Your AppealThis page provides general information about appeal strategy. It is not legal or medical advice. Apellica is not a law firm. Outcomes depend on documentation, plan terms, and timing.